Medicago's COVID-19 vaccine triggers immune response in early-stage trial ...Middle East

The company, which is backed by Mitsubishi Tanabe Pharma and tobacco giant Philip Morris , said it planned to move into mid-to-late-stage trials with a lower dose version of its vaccine, along with the GSK adjuvant. "What we're most encouraged with is that we are able to go with the lowest dose for our phase 2/3 trials," Medicago's Chief Executive Officer Bruce Clark told Reuters. Trials from rival coronavirus vaccine developers have generally shown that lower doses produce less side effects.

Hence then, the article about medicago 39 s covid 19 vaccine triggers immune response in early stage trial was published today ( Tuesday 10/11/2020 - 02:31 PM ) and is available on Yahoo ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Medicago's COVID-19 vaccine triggers immune response in early-stage trial )

Also on site :

• 2 die in apparent murder-suicide at La Habra Korean BBQ restaurant
• Russia to test all labor migrants for hepatitis
• Skelton: Katie Porter’s meltdown opens the door for this L.A. Democrat